Literature DB >> 25795308

Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation.

Anna M Blom1, Anders Österborg2, Tom E Mollnes3, Marcin Okroj4.   

Abstract

An emerging number of diseases and therapeutic approaches with defined involvement of the complement system justify a need for specific markers reflecting activation of particular effector arms of the complement cascade. Measurement of such soluble markers in circulation is a challenge since the specificity of antibodies must be limited to activated complement fragments but not predominant and ubiquitous parental molecules. Existing assays for the measurement of soluble, activated complement proteins are based on the detection of conformational neoepitopes. We tested an alternative approach based on detection of short linear neoepitopes exposed at the cleavage sites after activation of the actual complement component. Obtained antibodies reactive to C4d and C5b fragments enabled us to set up highly specific sandwich ELISAs, which ensured trustful measurements without false positive readouts characteristic for some of the widely used assays.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; C4d; C5b; Complement system; Leukemia; Lymphoma

Mesh:

Substances:

Year:  2015        PMID: 25795308     DOI: 10.1016/j.molimm.2015.02.029

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  15 in total

Review 1.  The complement system as a potential therapeutic target in rheumatic disease.

Authors:  Leendert A Trouw; Matthew C Pickering; Anna M Blom
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

2.  Increase in the Complement Activation Product C4d and the Terminal Complement Complex sC5b-9 Is Associated with Disease Severity and a Fatal Outcome in Necrotizing Soft-Tissue Infection.

Authors:  Morten Hedetoft; Martin Bruun Madsen; Cecilie Bo Hansen; Ole Hyldegaard; Peter Garred
Journal:  J Innate Immun       Date:  2021-12-14       Impact factor: 7.111

3.  The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis.

Authors:  André Struglics; Marcin Okroj; Per Swärd; Richard Frobell; Tore Saxne; L Stefan Lohmander; Anna M Blom
Journal:  Arthritis Res Ther       Date:  2016-10-06       Impact factor: 5.156

4.  Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis.

Authors:  Marcin Okrój; Martin Johansson; Tore Saxne; Anna M Blom; Roger Hesselstrand
Journal:  Arthritis Res Ther       Date:  2016-11-18       Impact factor: 5.156

5.  Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus.

Authors:  Myriam Martin; Karolina I Smoląg; Albin Björk; Birgitta Gullstrand; Marcin Okrój; Jonatan Leffler; Andreas Jönsen; Anders A Bengtsson; Anna M Blom
Journal:  Arthritis Res Ther       Date:  2017-12-06       Impact factor: 5.156

6.  Complement C4d-specific antibodies for the diagnosis of lung cancer.

Authors:  Daniel Ajona; Marcin Okrój; María J Pajares; Jackeline Agorreta; María D Lozano; Javier J Zulueta; Carla Verri; Luca Roz; Gabriella Sozzi; Ugo Pastorino; Pierre P Massion; Luis M Montuenga; Anna M Blom; Ruben Pio
Journal:  Oncotarget       Date:  2017-12-26

7.  Measuring plasma C4D to monitor immune complexes in lupus nephritis.

Authors:  Tineke Kraaij; Sara C Nilsson; Cees van Kooten; Marcin Okrój; Anna M Blom; Yk Onno Teng
Journal:  Lupus Sci Med       Date:  2019-06-03

8.  Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.

Authors:  Anna M Blom; Fernando Corvillo; Michal Magda; Grzegorz Stasiłojć; Pilar Nozal; Miguel Ángel Pérez-Valdivia; Virginia Cabello-Chaves; Santiago Rodríguez de Córdoba; Margarita López-Trascasa; Marcin Okrój
Journal:  J Clin Immunol       Date:  2016-05-05       Impact factor: 8.317

9.  A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity.

Authors:  Regina Michelis; Tamar Tadmor; Masad Barhoum; Mona Shehadeh; Lev Shvidel; Ariel Aviv; Galia Stemer; Najib Dally; Naomi Rahimi-Levene; Mona Yuklea; Andrei Braester
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

10.  Local complement activation is associated with primary graft dysfunction after lung transplantation.

Authors:  Hrishikesh S Kulkarni; Kristy Ramphal; Lina Ma; Melanie Brown; Michelle Oyster; Kaitlyn N Speckhart; Tsuyoshi Takahashi; Derek E Byers; Mary K Porteous; Laurel Kalman; Ramsey R Hachem; Melanie Rushefski; Ja'Nia McPhatter; Marlene Cano; Daniel Kreisel; Masina Scavuzzo; Brigitte Mittler; Edward Cantu; Katrine Pilely; Peter Garred; Jason D Christie; John P Atkinson; Andrew E Gelman; Joshua M Diamond
Journal:  JCI Insight       Date:  2020-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.